Home  /   Products  /   Nervous system  /   Ipidacrine (Axamon) 20 mg – [50 tablets]

Ipidacrine (Axamon) 20 mg – [50 tablets]


Cholinesterase inhibitors

SKU: 60921 Category:


Axamon Pharmacodynamics
Reversible cholinesterase inhibitor. Due to blockade of potassium channels of cell membranes and inhibition of cholinesterase activity, it stimulates neuromuscular transmission and impulse conduction in nervous system. It has M- and H-cholinomimetic action. It increases the effect of acetylcholine, serotonin, histamine and oxytocin on smooth muscles, resulting in increased contractility of smooth muscle organs, including GI and bronchi, decreases heart rate, increases salivary glands secretion, myometrium contractile activity, skeletal muscle tone. It has stimulating effect on CNS in combination with some sedative effects; it helps to improve learning ability and memory.

– Peripheral nervous system disorders (neuritis, polyneuritis and polyneuropathy, polyradiculopathy, myasthenia gravis and myasthenic syndrome of different etiology);
– recovery period of organic lesions of the central nervous system, accompanied by motor disorders, including bulbar paralysis and paresis;
– complex therapy of demyelinating diseases;
– senile dementia, Alzheimer’s disease, encephalopathies of various genesis.

Contraindications .
Hypersensitivity to any drug component, epilepsy, extrapyramidal disorders with hyperkinesias, angina pectoris, marked bradycardia, bronchial asthma, mechanical obstruction of the intestine or urinary tract, Vestibular disorders, acute gastric or duodenal ulcer, galactose intolerance, lactase deficiency or glucose-galactose malabsorption, pregnancy and lactation, children under 18 years of age.
With caution in: gastric and duodenal ulcer in remission, thyrotoxicosis, intracardiac conduction disorders; obstructive pulmonary disease in anamnesis or acute respiratory diseases.

Dosage and administration

  • Inside. Doses and duration of treatment should be determined individually depending on the severity of the disease.
  • Peripheral nervous system diseases, myasthenia gravis and myasthenic syndrome: 10-20 mg 1-3 times a day. The course of treatment is one to two months. If necessary, the course of treatment may be repeated several times with a break between courses of 1-2 months.
  • Alzheimer’s disease, encephalopathies, convalescent period of organic diseases of the central nervous system accompanied by movement disorders, including bulbar paralysis and paresis: the daily dose is adjusted individually, usually 10-20 mg 2-3 times a day.
    In demyelinating lesions of the nervous system, the dose may be increased to 20-40 mg 5-6 times a day.
  • The maximum daily dose is 200 mg.
    If one of the doses was missed, the usual dose of the drug is taken at the next appointment.